Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo.

Article Details

Citation
Copy to clipboard

Li M, Rao C, Pei D, Wang L, Li Y, Gao K, Wang M, Wang J

Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo.

Cancer Cell Int. 2014 Jan 27;14(1):8. doi: 10.1186/1475-2867-14-8.

PubMed ID
24467885 [ View in PubMed
]
Abstract

OBJECTIVE: A recombinant antitumor/antiviral protein (Novaferon, Nova) is a new type of interferon, which is produced by artificial design technology combining DNA-shuffling and High Throughput Screening (HTS). METHODS: The in vitro biological activities, such as anti-tumor activity and antiviral activity of Nova and recombinant human interferon alpha-2b (rhIFN-alpha2b) was performed; in vivo anti-tumor activity in nude mice was also tested. Flow cytometry, histo-pathological analysis including HE staining and immunohistochemistry, and surface plasmon resonance assay were performed to investigate the underlying mechanisms analysis. RESULTS: Nova exhibited stronger anti-cancer effects compared to rhIFN-alpha2b in vitro and in vivo. The antitumor mechanisms of Nova may be related to S phase arrest, pro-apoptosis, and inhibition of tumor angiogenesis. Moreover, Nova exhibited a higher binding affinity for IFN receptor 2 (IFNR2) than rhIFN-alpha2b, which is one of the possible reasons accounting for its stronger actions against tumor cells compared with rhIFN-alpha2b. CONCLUSION: Nova has strong antitumor activity and could be a potentially effective therapeutic drug for cancer.

DrugBank Data that Cites this Article

Drugs